GSWM
INO icon

Golden State Wealth Management’s Inovio Pharmaceuticals INO Stock Holding History

Golden State Wealth Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11 Hold
10
– – ﹤0.01% 1611
2026
Q1 		$17 Hold
10
– – ﹤0.01% 1593
2025
Q4 		$17 Hold
10
– – ﹤0.01% 1664
2025
Q3 		$23 Hold
10
– – ﹤0.01% 1652
2025
Q2 		$20 Hold
10
– – ﹤0.01% 1562
2025
Q1 		$16 Hold
10
– – ﹤0.01% 1583
2024
Q4 		$18 Buy
+10
New +$44 ﹤0.01% 1506

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Golden State Wealth Management's INO Position: Q2 2026 in Review

Golden State Wealth Management held its Inovio Pharmaceuticals (INO) position steady in Q2 2026 at 10 shares worth $11. The position accounts for ﹤0.01% of the portfolio, ranked #1611.

Golden State Wealth Management first reported a position in INO in Q4 2024 and has held it in 7 quarters since. The position peaked at $23 in Q3 2025. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Golden State Wealth Management held 10 shares of Inovio Pharmaceuticals worth $11 as of Q2 2026.
  • Golden State Wealth Management left its Inovio Pharmaceuticals share count unchanged in Q2 2026.
  • Inovio Pharmaceuticals made up ﹤0.01% of Golden State Wealth Management's portfolio in Q2 2026, its #1611 holding.
  • Golden State Wealth Management first reported a position in Inovio Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Golden State Wealth Management's Inovio Pharmaceuticals position peaked at $23 in Q3 2025.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.